Drugs / Albutein® 20%
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04835480 Comparator | Mar 2021 → Jun 2022 overdue | cirrhosis of liver | Healthgen Biotechnology Corp. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Albutein 20% | “Albutein® 20% (ALBUMIN HUMAN INFUSION 20% 50ML)” NCT04835480 ↗ |
| Known as | HSA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04835480 ↗ |
| Modality | Protein / enzyme biologic | “human serum albumin as an alternative to human plasma” PMID 40555465 ↗ Aug 2025 |
| Route | Intravenous | “10 g and 20 g IV everyday” NCT04835480 ↗ |